Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL) having a better day than most. The biotech is up more than 1% on a day when the indexes are struggling. Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL) net profit margin is -17.50% and weekly performance is 14.74%. On last trading day company shares ended up $22.73. Analysts mean target price for the company is $27.00. Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL) distance from 50-day simple moving average (SMA50) is -8.76%.
Orexigen Therapeutics, Inc. (NASDAQ:OREX) announced corporate and financial results for the first quarter ended March 31, 2014. For the three months ended March 31, 2014, Orexigen reported a net loss of $24.9 million, or $0.23 per share, as compared to a net loss of $19.4 million, or $0.21 per share, for the first quarter of 2013. Total operating expenses for the first quarter of 2014 were $24.0 million compared to $20.3 million for the first quarter of 2013. Orexigen Therapeutics, Inc. (NASDAQ:OREX) shares advanced 6.10% in last trading session and ended the day on $6.26. OREX return on assets is -63.60%. Orexigen Therapeutics, Inc. (NASDAQ:OREX) quarterly performance is -15.18%.
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced that it will provide an overview of the Company’s business at upcoming investor conferences: The Jefferies Global Healthcare Conference in New York City. Timothy P. Clackson, Ph.D., president of research and development and chief scientific officer, will present on Wednesday, June 4 at 2:30 p.m. (ET)
The Goldman Sachs 35th Annual Global Healthcare Conference in Rancho Palos Verdes, CA. Harvey J. Berger, M.D., chairman and chief executive officer, will present on Wednesday, June 11 at 2:40 p.m. (PT). Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) shares moved down -1.85% in last trading session and was closed at $6.37, while trading in range of $6.36 – $6.69. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) year to date (YTD) performance is -6.60%.
On 8 MAY Athersys, Inc. (NASDAQ:ATHX) announced interim 8-week results from the Phase 2 clinical study of MultiStem cell therapy to treat refractory ulcerative colitis (UC) being conducted by Pfizer Inc., demonstrating favorable safety and tolerability for MultiStem treatment, but failing to show significant improvement compared to placebo in the primary efficacy endpoints; Athersys, Inc. (NASDAQ:ATHX) ended the last trading day at $1.63. Company weekly volatility is calculated as 6.12% and price to cash ratio as 2.79. Athersys, Inc. (NASDAQ:ATHX) showed a positive weekly performance of 8.67%.
On 27 MAY Eisai Co., Ltd (ADR) (OTCMKTS: ESALY) announced that it will launch its new carbonated supplement drink Chocola BB Sparkling Salty Natsumikan* Flavor, classified as a Food with Nutrient Function Claims, in Japan on Monday, June 2. Eisai Co., Ltd (ADR) (OTCMKTS: ESALY) on last trading day company shares ended up $41.20.